Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Clinical Status, Drug Resistance, and Countermeasures of CAR-T Cell Cancer Immunotherapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Mechanisms of resistance to CAR T cell therapies

Resistance and recurrence of malignancies after CAR-T cell therapy

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Current progress in CAR-T cell therapy for tumor treatment

CAR-T Cells for Cancer Immunotherapy—the Barriers Ahead and the Paths Through

Current state of CAR-T therapy for T-cell malignancies

Recent advances in CAR-T cell engineering

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Current Clinical Application of the CAR-T Cell Therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

The Brief Introduction Of CAR-T Cell Therapy in Cancer Tumors

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges